Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

Johnson & Johnson (NYSE: JNJ) traded lower on Wednesday after the MedTech giant disclosed a temporary pause in U.S. cases treated with its Varipulse Pulsed Field Ablation Platform, which targets ...

“out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. Varipulse cases while it investigates the cause of four reported ...

Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ('Johnson & Johnson') (NYSE:JNJ) concerning ...

Johnson & Johnson halted U.S. Varipulse cases after four reported neurovascular events during external evaluation trials. Over 130 U.S. cases and 3,000 global commercial cases have been performed ...

Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

In MedTech, J&J's pulsed field ablation system Varipulse will need to prove competitive in the high-growth atrial filbrillation market against offerings from Boston Scientific and Medtronic ...

RYBREVANT and LAZCLUZE in lung cancer and VARIPULSE and the Dual Energy THERMOCOOL SMARTTOUCH SF Catheter in electrophysiology. In closing, I want to thank everyone at Johnson & Johnson for all ...